These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35235052)

  • 1. Development and characterization of anti-fibrotic natural compound similars with improved effectivity.
    Kreutzer FP; Meinecke A; Mitzka S; Hunkler HJ; Hobuß L; Abbas N; Geffers R; Weusthoff J; Xiao K; Jonigk DD; Fiedler J; Thum T
    Basic Res Cardiol; 2022 Mar; 117(1):9. PubMed ID: 35235052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction.
    Schimmel K; Jung M; Foinquinos A; José GS; Beaumont J; Bock K; Grote-Levi L; Xiao K; Bär C; Pfanne A; Just A; Zimmer K; Ngoy S; López B; Ravassa S; Samolovac S; Janssen-Peters H; Remke J; Scherf K; Dangwal S; Piccoli MT; Kleemiss F; Kreutzer FP; Kenneweg F; Leonardy J; Hobuß L; Santer L; Do QT; Geffers R; Braesen JH; Schmitz J; Brandenberger C; Müller DN; Wilck N; Kaever V; Bähre H; Batkai S; Fiedler J; Alexander KM; Wertheim BM; Fisch S; Liao R; Diez J; González A; Thum T
    Circulation; 2020 Mar; 141(9):751-767. PubMed ID: 31948273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between Circular RNA CDR1as and Post-Infarction Cardiac Function in Pig Ischemic Heart Failure: Influence of the Anti-Fibrotic Natural Compounds Bufalin and Lycorine.
    Mester-Tonczar J; Winkler J; Einzinger P; Hasimbegovic E; Kastner N; Lukovic D; Zlabinger K; Spannbauer A; Traxler D; Batkai S; Thum T; Gyöngyösi M
    Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32823854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Featured Article: TGF-β1 dominates extracellular matrix rigidity for inducing differentiation of human cardiac fibroblasts to myofibroblasts.
    Cho N; Razipour SE; McCain ML
    Exp Biol Med (Maywood); 2018 Apr; 243(7):601-612. PubMed ID: 29504479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endoplasmic Reticulum Protein TXNDC5 Augments Myocardial Fibrosis by Facilitating Extracellular Matrix Protein Folding and Redox-Sensitive Cardiac Fibroblast Activation.
    Shih YC; Chen CL; Zhang Y; Mellor RL; Kanter EM; Fang Y; Wang HC; Hung CT; Nong JY; Chen HJ; Lee TH; Tseng YS; Chen CN; Wu CC; Lin SL; Yamada KA; Nerbonne JM; Yang KC
    Circ Res; 2018 Apr; 122(8):1052-1068. PubMed ID: 29535165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
    Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
    Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac fibrosis models using human induced pluripotent stem cell-derived cardiac tissues allow anti-fibrotic drug screening in vitro.
    Iseoka H; Miyagawa S; Sakai Y; Sawa Y
    Stem Cell Res; 2021 Jul; 54():102420. PubMed ID: 34126557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-fibrotic effect of pirfenidone in muscle derived-fibroblasts from Duchenne muscular dystrophy patients.
    Zanotti S; Bragato C; Zucchella A; Maggi L; Mantegazza R; Morandi L; Mora M
    Life Sci; 2016 Jan; 145():127-36. PubMed ID: 26679108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-378 suppresses myocardial fibrosis through a paracrine mechanism at the early stage of cardiac hypertrophy following mechanical stress.
    Yuan J; Liu H; Gao W; Zhang L; Ye Y; Yuan L; Ding Z; Wu J; Kang L; Zhang X; Wang X; Zhang G; Gong H; Sun A; Yang X; Chen R; Cui Z; Ge J; Zou Y
    Theranostics; 2018; 8(9):2565-2582. PubMed ID: 29721099
    [No Abstract]   [Full Text] [Related]  

  • 10. Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.
    Epstein Shochet G; Wollin L; Shitrit D
    Respirology; 2018 Aug; 23(8):756-763. PubMed ID: 29532550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of Quiescent Cardiac Fibroblasts From Human Induced Pluripotent Stem Cells for In Vitro Modeling of Cardiac Fibrosis.
    Zhang H; Tian L; Shen M; Tu C; Wu H; Gu M; Paik DT; Wu JC
    Circ Res; 2019 Aug; 125(5):552-566. PubMed ID: 31288631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiomyocytes facing fibrotic conditions re-express extracellular matrix transcripts.
    Heras-Bautista CO; Mikhael N; Lam J; Shinde V; Katsen-Globa A; Dieluweit S; Molcanyi M; Uvarov V; Jütten P; Sahito RGA; Mederos-Henry F; Piechot A; Brockmeier K; Hescheler J; Sachinidis A; Pfannkuche K
    Acta Biomater; 2019 Apr; 89():180-192. PubMed ID: 30862552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro Mechanical Stimulation to Reproduce the Pathological Hallmarks of Human Cardiac Fibrosis on a Beating Chip and Predict The Efficacy of Drugs and Advanced Therapies.
    Visone R; Paoletti C; Cordiale A; Nicoletti L; Divieto C; Rasponi M; Chiono V; Occhetta P
    Adv Healthc Mater; 2024 Feb; 13(4):e2301481. PubMed ID: 37941521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-143-3p promotes human cardiac fibrosis via targeting sprouty3 after myocardial infarction.
    Li C; Li J; Xue K; Zhang J; Wang C; Zhang Q; Chen X; Gao C; Yu X; Sun L
    J Mol Cell Cardiol; 2019 Apr; 129():281-292. PubMed ID: 30878395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTGF/CCN2 is an autocrine regulator of cardiac fibrosis.
    Dorn LE; Petrosino JM; Wright P; Accornero F
    J Mol Cell Cardiol; 2018 Aug; 121():205-211. PubMed ID: 30040954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of TGF-β pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro.
    Stahnke T; Kowtharapu BS; Stachs O; Schmitz KP; Wurm J; Wree A; Guthoff RF; Hovakimyan M
    PLoS One; 2017; 12(2):e0172592. PubMed ID: 28231275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pirfenidone Has Anti-fibrotic Effects in a Tissue-Engineered Model of Human Cardiac Fibrosis.
    Bracco Gartner TCL; Crnko S; Leiteris L; van Adrichem I; van Laake LW; Bouten CVC; Goumans MJ; Suyker WJL; Sluijter JPG; Hjortnaes J
    Front Cardiovasc Med; 2022; 9():854314. PubMed ID: 35360018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-dependent functional crosstalk between cardiac fibroblasts and cardiomyocytes in a 3D engineered cardiac tissue.
    Li Y; Asfour H; Bursac N
    Acta Biomater; 2017 Jun; 55():120-130. PubMed ID: 28455218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor 23 is induced by an activated renin-angiotensin-aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts.
    Leifheit-Nestler M; Kirchhoff F; Nespor J; Richter B; Soetje B; Klintschar M; Heineke J; Haffner D
    Nephrol Dial Transplant; 2018 Oct; 33(10):1722-1734. PubMed ID: 29425341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy.
    Morfino P; Aimo A; Castiglione V; Gálvez-Montón C; Emdin M; Bayes-Genis A
    Heart Fail Rev; 2023 Mar; 28(2):555-569. PubMed ID: 36221014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.